ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MK-1403

A development code. Also written as “MK-1403 formulation (FM) 1 + additive”, “MK-1403 FM2 + additive” and “MK-1403 + additive coformulation”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Merck.

Furthest: phase 1, since Nov 17, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck20 open or runningphase 1since Nov 17, 2025Nov 17, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07242469 · 53 enrolled · United States
  2. Jun 24, 2026Phase 1 study in HealthyNCT07677163 · 15 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07677163Healthy · United States1CompletedOct 5, 202615
NCT07242469Diabetes Mellitus, Type 2 · United States1CompletedSep 2, 202653

How it is read

Names in the registry

  • “MK-1403 formulation (FM) 1 + additive”, 1 entry
  • “MK-1403 FM2 + additive”, 1 entry
  • “MK-1403 + additive coformulation”, 1 entry

Codes read as this program: MK1403.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.